Teladoc Health Statistics
Total Valuation
Teladoc Health has a market cap or net worth of $1.20 billion. The enterprise value is $1.48 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, after market close.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Teladoc Health has 180.51 million shares outstanding. The number of shares has increased by 3.08% in one year.
| Current Share Class | 180.51M |
| Shares Outstanding | 180.51M |
| Shares Change (YoY) | +3.08% |
| Shares Change (QoQ) | +0.73% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 74.06% |
| Float | 179.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| Forward PS | 0.47 |
| PB Ratio | 0.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 4.27 |
| P/OCF Ratio | 4.16 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 31.24, with an EV/FCF ratio of 5.30.
| EV / Earnings | n/a |
| EV / Sales | 0.59 |
| EV / EBITDA | 31.24 |
| EV / EBIT | n/a |
| EV / FCF | 5.30 |
Financial Position
The company has a current ratio of 2.80, with a Debt / Equity ratio of 0.78.
| Current Ratio | 2.80 |
| Quick Ratio | 2.40 |
| Debt / Equity | 0.78 |
| Debt / EBITDA | 17.03 |
| Debt / FCF | 3.71 |
| Interest Coverage | -8.14 |
Financial Efficiency
Return on equity (ROE) is -12.39% and return on invested capital (ROIC) is -3.65%.
| Return on Equity (ROE) | -12.39% |
| Return on Assets (ROA) | -3.14% |
| Return on Invested Capital (ROIC) | -3.65% |
| Return on Capital Employed (ROCE) | -6.54% |
| Weighted Average Cost of Capital (WACC) | 9.09% |
| Revenue Per Employee | $449,009 |
| Profits Per Employee | -$30,562 |
| Employee Count | 5,600 |
| Asset Turnover | 0.80 |
| Inventory Turnover | 22.20 |
Taxes
| Income Tax | -13.96M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.09% in the last 52 weeks. The beta is 2.08, so Teladoc Health's price volatility has been higher than the market average.
| Beta (5Y) | 2.08 |
| 52-Week Price Change | -6.09% |
| 50-Day Moving Average | 5.46 |
| 200-Day Moving Average | 6.87 |
| Relative Strength Index (RSI) | 71.72 |
| Average Volume (20 Days) | 5,103,980 |
Short Selling Information
The latest short interest is 29.71 million, so 16.46% of the outstanding shares have been sold short.
| Short Interest | 29.71M |
| Short Previous Month | 31.98M |
| Short % of Shares Out | 16.46% |
| Short % of Float | 16.58% |
| Short Ratio (days to cover) | 6.89 |
Income Statement
In the last 12 months, Teladoc Health had revenue of $2.51 billion and -$171.15 million in losses. Loss per share was -$0.96.
| Revenue | 2.51B |
| Gross Profit | 1.74B |
| Operating Income | -157.19M |
| Pretax Income | -185.11M |
| Net Income | -171.15M |
| EBITDA | 47.51M |
| EBIT | -157.19M |
| Loss Per Share | -$0.96 |
Full Income StatementBalance Sheet
The company has $750.74 million in cash and $1.04 billion in debt, with a net cash position of -$287.31 million or -$1.59 per share.
| Cash & Cash Equivalents | 750.74M |
| Total Debt | 1.04B |
| Net Cash | -287.31M |
| Net Cash Per Share | -$1.59 |
| Equity (Book Value) | 1.34B |
| Book Value Per Share | 7.41 |
| Working Capital | 727.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $287.95 million and capital expenditures -$7.83 million, giving a free cash flow of $280.13 million.
| Operating Cash Flow | 287.95M |
| Capital Expenditures | -7.83M |
| Depreciation & Amortization | 204.70M |
| Net Borrowing | -550.63M |
| Free Cash Flow | 280.13M |
| FCF Per Share | $1.55 |
Full Cash Flow StatementMargins
Gross margin is 69.29%, with operating and profit margins of -6.25% and -6.81%.
| Gross Margin | 69.29% |
| Operating Margin | -6.25% |
| Pretax Margin | -7.36% |
| Profit Margin | -6.81% |
| EBITDA Margin | 1.89% |
| EBIT Margin | -6.25% |
| FCF Margin | 11.14% |
Dividends & Yields
Teladoc Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.08% |
| Shareholder Yield | -3.08% |
| Earnings Yield | -14.30% |
| FCF Yield | 23.41% |
Analyst Forecast
The average price target for Teladoc Health is $7.41, which is 11.77% higher than the current price. The consensus rating is "Hold".
| Price Target | $7.41 |
| Price Target Difference | 11.77% |
| Analyst Consensus | Hold |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 2.17% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Teladoc Health has an Altman Z-Score of -6.69 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.69 |
| Piotroski F-Score | 4 |
